Targeted therapies in the management of renal cell carcinoma: role of bevacizumab
Bernard Escudier1, Jan Cosaert2, Sangeeta Jethwa21Unité Immunothérapie, Institut Gustave Roussy, Villejuif, France; 2F. Hoffmann-La Roche Ltd, Basel, SwitzerlandAbstract: Bevacizumab (10 mg/kg every 2 weeks), in combination with interferon alpha-2a (IFN), is an effectiv...
Guardado en:
Autores principales: | Bernard Escudier, Jan Cosaert, Sangeeta Jethwa |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2008
|
Materias: | |
Acceso en línea: | https://doaj.org/article/d19bb4fcab0d4f1794b552ac3168d89d |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Rationale for targeted therapies and potential role of pazopanib in advanced renal cell carcinoma
por: Peter E Clark
Publicado: (2010) -
Bevacizumab in the therapy for refractory metastatic colorectal cancer
por: Mary F Mulcahy
Publicado: (2008) -
Tivozanib in the treatment of renal cell carcinoma
por: Hepgur M, et al.
Publicado: (2013) -
Current use and potential role of bevacizumab in the treatment of gastrointestinal cancers
por: Jia Li, et al.
Publicado: (2009) -
A Case of Pseudoprogression in Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab
por: Yukinobu Watanabe MD, PhD, et al.
Publicado: (2021)